Cargando…
Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice
BACKGROUND: Treatment of Mycobacterium ulcerans disease, or Buruli ulcer (BU), has shifted from surgery to treatment with streptomycin(STR)+rifampin(RIF) since 2004 based on studies in a mouse model and clinical trials. We tested two entirely oral regimens for BU treatment, rifampin(RIF)+clarithromy...
Autores principales: | Almeida, Deepak, Converse, Paul J., Ahmad, Zahoor, Dooley, Kelly E., Nuermberger, Eric L., Grosset, Jacques H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014976/ https://www.ncbi.nlm.nih.gov/pubmed/21245920 http://dx.doi.org/10.1371/journal.pntd.0000933 |
Ejemplares similares
-
Bactericidal Activity Does Not Predict Sterilizing Activity: The Case of Rifapentine in the Murine Model of Mycobacterium ulcerans Disease
por: Almeida, Deepak V., et al.
Publicado: (2013) -
BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse
por: Converse, Paul J., et al.
Publicado: (2011) -
Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease
por: Converse, Paul J., et al.
Publicado: (2015) -
Rapid, Serial, Non-invasive Assessment of Drug Efficacy in Mice with Autoluminescent Mycobacterium ulcerans Infection
por: Zhang, Tianyu, et al.
Publicado: (2013) -
Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease
por: Converse, Paul J., et al.
Publicado: (2014)